Transdermal fentanyl: Little absorption in two patients with systemic sclerosis?

Pain Medicine

Volumn 2, Issue 3, 2001, Pages 225-227

  Karst, Matthias ^a   Fink, Matthias ^a   Wagner, Till ^a   Conrad, Ingomar ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Conversion equations; Methadone; Morphine; Systemic sclerosis; Transdermal fentanyl; Transdermal testosterone

Indexed keywords

AZATHIOPRINE; BUPIVACAINE; FENTANYL; ILOPROST; METHADONE; MORPHINE; MORPHINE SULFATE; OMEPRAZOLE; PREDNISONE; PROSTAGLANDIN E1; TESTOSTERONE;

ADULT; ARM; ARTICLE; CASE REPORT; DELTOID MUSCLE; DRUG ABSORPTION; GASTROINTESTINAL SYMPTOM; HUMAN; ISCHEMIA; MALE; PAIN; RISK ASSESSMENT; SKIN DISEASE; SYSTEMIC SCLEROSIS; TENDINITIS; THUMB; TRANSDERMAL PATCH;

EID: 0035215430     PISSN: 15262375     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4637.2001.01028.x     Document Type: Article

References (10)

1. Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men
2. Microvascular involvement in systemic sclerosis: Capillaroscopic findings
3. Scleroderma
4. Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain
5. A study to examine the repeat dose pharmacokinetics of TTS (fentanyl) using repeated 72-hour applications for a 6 day period in patients with cancer pain or intractable pain requiring opioid therapy Janssen
6. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics
7. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficiacy in pain control
8. Androgen replacement therapy
9. Fentanyl remaining in a transdermal system following three days of continuous use